Ticagrelor with or without Aspirin in High-Risk Patients after PCI
New England Journal of Medicine2019Vol. 381(21), pp. 2032–2042
Citations Over TimeTop 1% of 2019 papers
Roxana Mehran, Usman Baber, Samin K. Sharma, David J. Cohen, Dominick J. Angiolillo, Carlo Briguori, Yichao Jin, Timothy Collier, George Dangas, Dariusz Dudek, Vladimír Džavík, Javier Escaned, Robert Gil, Paul A. Gurbel, Christian W. Hamm, Timothy D. Henry, Kurt Huber, Adnan Kastrati, Upendra Kaul, Ran Kornowski, Mitchell W. Krucoff, Vijay Kunadian, Steven O. Marx, Shamir R. Mehta, David J. Moliterno, E. Magnus Ohman, Keith G. Oldroyd, Gennaro Sardella, Samantha Sartori, Richard Shlofmitz, Philippe Gabríel Steg, Giora Weisz, Bernhard Witzenbichler, Yaling Han, Stuart Pocock, C. Michael Gibson
Abstract
Among high-risk patients who underwent PCI and completed 3 months of dual antiplatelet therapy, ticagrelor monotherapy was associated with a lower incidence of clinically relevant bleeding than ticagrelor plus aspirin, with no higher risk of death, myocardial infarction, or stroke. (Funded by AstraZeneca; TWILIGHT ClinicalTrials.gov number, NCT02270242.).
Related Papers
- → Acute Coronary Syndrome Antiplatelet Alternatives in Clopidogrel Allergy(2014)9 cited
- → Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor(2013)7 cited
- → OUTCOMES IN PATIENTS TREATED WITH TICAGRELOR OR CLOPIDOGREL AFTER ACUTE CORONARY SYNDROME: EXPERIENCES FROM SWEDEHEART REGISTRY(2016)1 cited
- → Ticagrelor in Acute Coronary Syndromes(2015)
- → Ticagrelor in Acute Coronary Syndromes(2015)